IHC - Microsatellite Instability for Colorectal Carcinoma MSH-6

The IHC – Microsatellite Instability (MSH6) test for Colorectal Carcinoma is a specialized immunohistochemistry (IHC) diagnostic test used to detect MSH6 protein expression in colorectal cancer tissue samples. MSH6 is an essential DNA mismatch repair (MMR) protein that helps correct errors occurring during DNA replication. Loss of MSH6 expression can indicate microsatellite instability (MSI) and may suggest the possibility of Lynch syndrome, a hereditary condition associated with colorectal and other cancers.

Microsatellite instability occurs when the DNA repair system is defective, allowing mutations to accumulate in tumor cells. Detecting MSH6 loss helps identify colorectal cancers with mismatch repair deficiency. These cancers may behave differently from other tumors and often show better response to certain treatments, including immune checkpoint inhibitor therapy.

The MSH6 IHC test is usually performed along with MLH1, MSH2, and PMS2 to provide a complete mismatch repair protein profile for colorectal cancer evaluation.

Benefits of the Test

The MSH6 MSI test offers several important benefits:

• Detects loss of MSH6 protein expression
• Identifies microsatellite instability in colorectal tumors
• Helps screen for Lynch syndrome
• Supports accurate colorectal cancer classification
• Guides immunotherapy and personalized treatment decisions
• Assesses inherited cancer risk for family screening

This test plays a vital role in modern precision oncology.

Why Doctors Recommend This Test

Doctors recommend the MSH6 IHC test when colorectal cancer is diagnosed or hereditary mismatch repair deficiency is suspected.

It is commonly advised for:

• Newly diagnosed colorectal cancer patients
• Early-onset colorectal carcinoma cases
• Patients with family history of Lynch syndrome
• Cases requiring mismatch repair deficiency screening
• Advanced colorectal tumor molecular profiling

The results help oncologists determine targeted therapy eligibility and support recommendations for genetic counseling.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected colorectal tissue biopsy or surgical tumor specimens.

Normal Reporting Time

The normal turnaround time for the MSH6 IHC test is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with colorectal carcinoma
• Individuals with family history of hereditary colorectal cancers
• Patients suspected of Lynch syndrome
• Cases requiring MSI evaluation
• Oncology patients needing personalized treatment planning

The IHC MSH6 test is a critical diagnostic tool in colorectal cancer management. It helps identify DNA mismatch repair defects, assess hereditary cancer risk, and guide advanced treatment strategies. Early diagnosis improves clinical outcomes and supports preventive family care.